10 recruiting, 6 completed, 5 active not recruiting, 3 terminated. 26 Phase 2, 8 Phase 1, 2 Phase 3.
Follow Metastatic Uveal Melanoma: new trials by email Literature Review of Metastatic Uveal Melanoma trials Research Report on Metastatic Uveal Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors VMD-102 - Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | VM Discovery, Inc. | 111 | 2026-07-16 | 2026-11-03 |
| Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide - Unresectable Melanoma, Metastatic Cutaneous Melanoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-04 |
| Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2025-12-31 | 2026-03-31 |
| Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. - Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic | Phase 1 / Phase 2 | Recruiting | Novelwise Pharmaceutical Corporation | 36 | 2025-11-20 | 2025-11-28 |
| Tebentafusp-tebn With LDT in Metastatic UM Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU - Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | Thomas Jefferson University | 109 | 2025-10-15 | 2026-07-21 |
| Adding IL-2 to Tebentafusp to Eradicate Cancer Progression Aldesleukin - Uveal Melanoma, Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | St Vincent's Hospital, Sydney | 8 | 2025-06-01 | 2025-07-14 |
| Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization - Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver | Phase 2 | Recruiting | University of Miami | 30 | 2025-02-14 | 2026-02-23 |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma RP2, Ipilimumab, Nivolumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Recruiting | Replimune, Inc. | 280 | 2024-12-17 | 2026-04-02 |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma ZIV-Aflibercept, Cemiplimab - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2024-11-04 | 2025-12-04 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Active not recruiting | IDEAYA Biosciences | 420 | 2023-10-31 | 2026-02-17 |
| Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma BRD4 Inhibitor PLX2853, Trametinib, Computed Tomography - Advanced Uveal Melanoma, Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Withdrawn | Alliance for Clinical Trials in Oncology | 2023-01-13 | 2023-08-18 | |
| Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) Pembrolizumab 25 MG/1 ML Intravenous Solution - Metastatic Uveal Melanoma | Phase 2 | Completed | Institut Curie | 51 | 2022-07-07 | 2026-07-28 |
| A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas DYP688 - Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 66 | 2022-07-04 | 2026-07-28 |
| Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma Binimetinib, Belinostat - Metastatic Uveal Melanoma | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2021-12-15 | 2026-04-06 |
| Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases Carmustine, Ethiodized Oil, Transarterial Chemoembolization - Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma | Phase 2 | Active not recruiting | Thomas Jefferson University | 28 | 2021-09-27 | 2026-05-06 |
| Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy - Metastatic Uveal Melanoma | Phase 2 | Terminated | Thomas Jefferson University | 13 | 2021-01-26 | 2025-07-15 |
| Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma Nivolumab, Relatlimab - Metastatic Uveal Melanoma | Phase 2 | Completed | Jose Lutzky, MD | 27 | 2020-11-10 | 2026-02-11 |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions IDE196, Binimetinib, Crizotinib - Metastatic Uveal Melanoma, Cutaneous Melanoma | Phase 1 / Phase 2 | Recruiting | IDEAYA Biosciences | 336 | 2019-06-28 | 2026-06-08 |
| Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver Ipilimumab, Nivolumab, Embolization Therapy - Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 14 | 2018-05-02 | 2026-07-07 |
| Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye Pembrolizumab, Entinostat - Metastatic Uveal Melanoma | Phase 2 | Completed | Vastra Gotaland Region | 29 | 2018-02-21 | 2023-12-08 |
Showing 20 of 26. Sign in to see all of them.
Uveal Melanoma (26) · Melanoma (9) · Neoplasm Metastasis (6) · Eye Neoplasms (3) · Colorectal Neoplasms (2) · Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Lung Neoplasms (1) · Recurrence (1)
Eye Diseases (26) · Neoplasms by Histologic Type (26) · Neoplasms by Site (26) · Neoplasms, Germ Cell and Embryonal (26) · Neoplasms, Nerve Tissue (26) · Neuroectodermal Tumors (26) · Neuroendocrine Tumors (26) · Nevi and Melanomas (26) · Uveal Diseases (26) · Uveal Neoplasms (26) · Neoplasms (24) · Eye Neoplasms (23) · Melanoma (17) · Skin Diseases (9) · Skin Neoplasms (9)
Nivolumab (6) · Ipilimumab (4) · pembrolizumab (3) · CTLA-4 Antigen (2) · Carmustine (2) · Crizotinib (2) · Cyclophosphamide (2) · Dacarbazine (2) · aldesleukin (2) · binimetinib (2) · fludarabine (2) · fludarabine phosphate (2) · tebentafusp (2) · trametinib (2) · Biopsy (1)
H. Lee Moffitt Cancer Center and Research Institute (3) · Thomas Jefferson University (3) · IDEAYA Biosciences (2) · National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · Beijing Biotech (1) · Eric Bernicker, MD (1) · GlaxoSmithKline (1) · Institut Curie (1) · Jose Lutzky, MD (1) · M.D. Anderson Cancer Center (1) · Novartis Pharmaceuticals (1) · Novelwise Pharmaceutical Corporation (1) · Replimune, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (19) · Australia (5) · France (3) · United Kingdom (3) · Canada (2) · Germany (2) · Netherlands (2) · Spain (2) · Switzerland (2) · Belgium (1) · China (1) · Israel (1) · Italy (1) · Poland (1) · Sweden (1)
Rino Seedor, MD (2) · Ahmad Tarhini, MD, PHD (1) · Ahmad Tarhini, MD, PhD (1) · Alexander N Shoushtari (1) · Anthony Joshua, FRACP (1) · Carin Gonsalves, MD (1) · Eric Bernicker, M.D. (1) · Ernest Marshall (1) · George Cole Jr., MD (1) · Hetal Patel, MD, MSHS, CHCQM (1) · Jay Wu, PhD (1) · Jonathan Zager, MD, FACS (1) · Jose Lutzky, MD (1) · Lynn Feun, MD (1)
PMID 16344433, PMID 28395880, PMID 31046743, PMID 33125309, PMID 33827976, PMID 34453044, PMID 34663687, PMID 37377898, PMID 42443515, PMID 9437317
2008 (1), N01CM00100 (1), N01CM62206 (1), P30CA008748 (1), R21CA208609 (1), U01CA069856 (1), UM1CA186689 (1)